A OVERVIEW ON BEDAQUILINE FOR THE TREATMENT OF DRUGRESISTANT TUBERCULOSIS
Pramod Kumar, M. Aravind, M Venkata Ramana, Mr Sivaram Kumar, Tuberculosis Opin, Drug Saf, Drug Saf, Van Heeswijk Rpg, et al. (42 authors)
International Journal of Biology Pharmacy and Allied Sciences · 2021-09
Abstract
Bedaquiline has been recently approved drug moiety for the treatment of pneumonic multidrug-safe tuberculosis (TB) as a component of mixed treatment in adults. Existing medicines for multi-drug safe tuberculosis (MDR-TB) have significant limitations, to the extent of their feasibility, result profile, and unconventionality of association. Bedaquiline is a novel diarylquinoline against microbial that has starting late been investigated as an assistant to existing medicines for MDR-TB. In this review, the overall properties of bedaquiline were consolidated like physicochemical properties, dose administration, mechanism of action, pharmacokinetics, pharmacodynamics,drug interactions, and side effects for better understanding.
MeSH terms
- Bedaquiline
- Tuberculosis
- Medicine